Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Ephedrine hydrochloride 30 mg/mL
Max Health Limited
Ephedrine hydrochloride 30 mg/mL
30 mg/mL
Solution for injection
Active: Ephedrine hydrochloride 30 mg/mL Excipient: Water for injection
Ampoule, glass, Type I with a one-point cut 1mL, 10 dose units
Class B2 Controlled Drug
Class B2 Controlled Drug
Siegfried PharmaChemikalien Minden GmbH
Indicated in the treatment of hypotension secondary to spinal anaesthesia in adults.
Package - Contents - Shelf Life: Ampoule, glass, Type I with a one-point cut 1mL - 10 dose units - 36 months from date of manufacture stored at or below 25°C protect from light
2011-06-08
NEW ZEALAND DATA SHEET 1 PRODUCT NAME Ephedrine Hydrochloride Injection 30mg/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ephedrine hydrochloride 30mg/ml For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Clear, colourless solution for Injection pH = 5.00 – 7.000 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ephedrine Hydrochloride Injection is indicated in the treatment of hypotension secondary to spinal anaesthesia. 4.2 DOSE AND METHOD OF ADMINISTRATION Ephedrine Hydrochloride Injection is administered by the intravenous route. _Adults and Elderly _ Ephedrine hydrochloride should be administered in the lowest effective dose. A 3 mg/mL solution should be given as a slow intravenous injection of 3 to 7.5 mg (maximum 10 mg), repeated as needed every 3 - 4 minutes to a maximum of 30 mg. A lack of efficacy after 30 mg should lead to reconsideration of the choice of therapeutic agent. _Children _ Ephedrine hydrochloride injection is not approved for use in this patient population. 4.3 CONTRAINDICATIONS Hypersensitivity to Ephedrine hydrochloride or to any of the excipients listed in section 6.1. • In combination with other indirect sympathomimetic agents such as phenylpropanolamine, phenylephrine, pseudoephedrine and methylphenidate. • In combination with alpha sympathomimetic agents. • In combination with non-selective Monoamine Oxidase Inhibitors (MAOI) or within 14 days of their withdrawal. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Ephedrine should be used with caution in patients who may be particularly susceptible to their effects, particularly those with hyperthyroidism. Great care is also needed in patients with Page 2 of 8 cardiovascular disease such as ischaemic heart disease, arrhythmia or tachycardia, occlusive vascular disorders including arteriosclerosis, hypertension, or aneurysms. Angina pain may be precipitated in patients with angina pectoris. Care is also required when Ephedrine is given to patients with diabetes mellitus, closed-angle gl Read the complete document